Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple SclerosisEline M. E. Coerver, Eva Strijbis, Caspar E.P. van Munster et al.|JAMA Neurology|2024Cited by 29
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)Alyssa A Toorop, Zoé L. E. van Kempen, Zoë YGJ van Lierop et al.|Journal of Neurology Neurosurgery & Psychiatry|2023Cited by 17
Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trialAlyssa A Toorop, Zoé L. E. van Kempen, Mark HJ Wessels et al.|Journal of the Neurological Sciences|2024Cited by 6
Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS)Wing Hee Fung, Eva Strijbis, Mark HJ Wessels et al.|Journal of Neurology|2025Cited by 4
Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patientsAlyssa A Toorop, Charlotte E. Teunissen, Mark HJ Wessels et al.|Multiple Sclerosis Journal|2024Cited by 3